QIAGEN, in collaboration with Myriad Genetics, has announced the development of a globally distributable next-generation sequencing (NGS) test kits for analyzing Homologous Recombination Deficiency (HRD) status in cancer patients.
The test is powered by QIAGEN’s proprietary QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary MyChoice CDx. The development project was initiated under the partnership between the two companies in October 2023.
According to the agreement, QIAGEN will gain the development and distribution rights of the product outside of the US. Financial terms of the transaction were undisclosed. The company will also be granted intellectual property rights to collaborate with pharmaceutical partners to create a companion diagnostic IVD-validated test to be used outside of the US.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.